Exelixis and Ipsen report positive Phase III Meteor trial data of Cabometyx tablets

Exelixis and Ipsen have announced positive subgroup analyses of the Phase III Meteor trial data of Cabometyx (cabozantinib) tablets to treat advanced renal cell carcinoma (RCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news